期刊
RSC MEDICINAL CHEMISTRY
卷 13, 期 10, 页码 1197-1204出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2md00158f
关键词
-
资金
- Individual Knowledge Research in FY 2012 Strategic Programs for R&D (President's Fund)
- Japan Agency for Medical Research and Development (AMED) [A120]
TRPV1-targeted compounds were synthesized by modifying the structure of SB366791, and higher antagonistic activities were achieved by avoiding amide-iminol tautomerization. Additionally, explorative PET imaging trials were conducted using labeled derivatives, providing a basis for further applications.
Transient receptor potential cation channel subfamily V member 1 (TRPV1)-targeted compounds were synthesized by modifying the structure of SB366791, a pharmaceutically representative TRPV1 antagonist. To avoid amide-iminol tautomerization, structurally supported N-methylated amides (i.e., 3-alkoxy-substitued N-meythylamide derivatives of SB366791) were evaluated using a Ca2+ influx assay, in which cells expressed recombinant TRPV1 in the presence of 1.0 mu M capsaicin. The antagonistic activities of N-(3-methoxyphenyl)-N-methyl-4-chlorocinnamamide (2) (RLC-TV1004) and N-{3-(3-fluoropropoxy)phenyl}-N-methyl-4-chlorocinnamamide (4) (RLC-TV1006) were found to be approximately three-fold higher (IC50: 1.3 mu M and 1.1 mu M, respectively) than that of SB366791 (IC50: 3.7 mu M). These results will help reinvigorate the potential of SB366791 in medicinal chemistry applications. The 3-methoxy and 3-fluoroalkoxy substituents were used to obtain radioactive [C-11]methoxy- or [F-18]fluoroalkoxy-incorporated tracers for in vivo positron emission tomography (PET). Using the C-11- or F-18-labeled derivatives, explorative PET imaging trials were performed in rats.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据